The approved, i.v.-administered CXCR4 antagonist, plerixafor (AMD3100) [39], had been evaluated in a number of BLM-induced pulmonary fibrosis models [23, 26, 27] including one recently-retracted article [40]. Here, CXCR4 is linked to pulmonary fibrosis.